Abstract: Small form-factor MEMS devices and methods of using the devices. An exemplary MEMS device includes an ACM. Certain devices comprise nanometer scale sensing gaps in the out-of-plane direction to increase vibration sensitivity in a vacuum casing. Certain devices described herein provide a differential sensing mechanism. Accelerometer contact microphones having an operational bandwidth ranging from 0 Hz and 10,000 Hz are also disclosed. The vibration acceleration sensitivity of certain devices described herein is better 100 ?g?Hz.

Abstract: An aspect of the present disclosure facilitates manual snapshot and restore of user applications hosted on cloud infrastructures. In one embodiment, a system receives setup data specifying a first set of actions (such as shutting off and restarting related services, etc.) to be performed upon receipt of a manual snapshot command with respect to a component of a user application hosted on a cloud infrastructure. Upon receiving the manual snapshot command to capture a current state of the component, the system performs the first set of actions along with capturing the current state of the component.

Abstract: Small form-factor MEMS devices and methods of using the devices are disclosed. An exemplary MEMS device includes an accelerometer contact microphone. Certain devices described herein comprise nanometer scale sensing gaps in the out-of-plane direction to increase vibration sensitivity in a vacuum casing. Certain devices described herein provide a differential sensing mechanism. The disclosure also describes accelerometer contact microphones having an operational bandwidth ranging from 0 Hz and 10,000 Hz. The vibration acceleration sensitivity of certain devices described herein is better 100 ?g?Hz.

Abstract: An aspect of the present disclosure facilitates mobility of user applications across cloud infrastructures. In one embodiment, a mobility server maintains a setup data which indicates that a user application is to be operative based on a specific set of application components when the user application is to be hosted on a cloud infrastructure. Upon receiving a request to move the user application currently executing in a source cloud infrastructure to the cloud infrastructure, mobility server provisions the specific set of application components in the cloud infrastructure in view of the setup data and then executes the user application in the cloud infrastructure based on the specific set of application components.

Abstract: A hermetically-sealed multi-directional single-proof-mass accelophone that demonstrates a high sensitivity to micro-gravity level accelerations in a wide operational bandwidth by utilizing nano-scale transductions gaps and vacuum packaging. Stable operation of the wafer-level-packaged sensor is validated over a wide operational bandwidth greater than 10 kHz. Developing a noise-matched custom interface IC should enable a sensor noise performance near the Brownian noise floor of below 10 ?g/?Hz. The sensor can be applied in detection of vital mechano-acoustic signals emanating from the body and can be easily incorporated in existing wearable health monitoring devices for multi-faceted health monitoring using a single integrated sensor.

Abstract: A composition comprising (S)—N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide and hypromellose acetate succinate for pharmaceutical preparations, especially capsule preparations.

Abstract: Small form-factor MEMS devices and methods of using the devices are disclosed. An exemplary MEMS device includes an accelerometer contact microphone. Certain devices described herein comprise nanometer scale sensing gaps in the out-of-plane direction to increase vibration sensitivity in a vacuum casing. Certain devices described herein provide a differential sensing mechanism. The disclosure also describes accelerometer contact microphones having an operational bandwidth ranging from 0 Hz and 10,000 Hz. The vibration acceleration sensitivity of certain devices described herein is better 100 ?g?Hz.

Abstract: An aspect of the present disclosure facilitates mobility of user applications across cloud infrastructures. In one embodiment, a mobility server maintains a setup data which indicates that a user application is to be operative based on a specific set of application components when the user application is to be hosted on a cloud infrastructure. Upon receiving a request to move the user application currently executing in a source cloud infrastructure to the cloud infrastructure, mobility server provisions the specific set of application components in the cloud infrastructure in view of the setup data and then executes the user application in the cloud infrastructure based on the specific set of application components.

Abstract: A composition comprising (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide and hypromellose acetate succinate for pharmaceutical preparations, especially capsule preparations.

Abstract: A composition comprising (S)—N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide and hypromellose acetate succinate for pharmaceutical preparations, especially capsule preparations.

Abstract: A composition comprising (S)—N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide and hypromellose acetate succinate for pharmaceutical preparations, especially capsule preparations.

Abstract: The present invention provides a process for preparing enterically-coated lyospheres comprising a therapeutic agent comprising: a.) providing lyospheres comprising the therapeutic agent; b.) coating said lyospheres with an enteric polymer coating composition; and c.) isolating said enterically-coated lyospheres. In other embodiments, the invention provides dosage forms comprising a lyosphere comprising an effective amount of a therapeutic agent and an enteric polymer coating. In some embodiments, the therapeutic agent in the process or dosage form is a polypeptide, a protein, a peptide, a lipopeptide, a glycoprotein, a fusion protein, a protein conjugate, a cytokine, an enzyme, an antibody, an oligonucleotide, a vaccine vector, small molecule, a live virus, an inactivated virus, a virus-like particle, a viral protein subunit, an adjuvant, microbiome, a prebiotic, a probiotic, or an ectobiotic.

Abstract: A composition comprising (S)—N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide and hypromellose acetate succinate for pharmaceutical preparations, especially capsule preparations.

Abstract: A system and method for maintaining a virtual computing system in a desired state defined by a service definition includes parsing, by a health-check system of the virtual computing system, the service definition for identifying a component to which the service definition applies. The component is one of a virtual machine and a container of the virtual computing system. To maintain the desired state, the health-check system is configured to collect operating values of one or more parameters from the component, determine that the component is in violation of the service definition based on the operating values of the one or more parameters, and troubleshoot the component upon finding the violation for maintaining the virtual computing system in the state defined by the service definition.

Abstract: Disclosed are formulations and tablets made therefrom comprising the compound of Formula IA or Formula IB which have sustained-release properties, and the dispersion containing the compounds of Formula IA or IB which facilitates such sustained release: Formula IA, Formula IB.

Abstract: The present invention provides a process for preparing enterically-coated lyospheres comprising a therapeutic agent comprising: a.) providing lyospheres comprising the therapeutic agent; b.) coating said lyospheres with an enteric polymer coating composition; and c.) isolating said enterically-coated lyospheres. In other embodiments, the invention provides dosage forms comprising a lyosphere comprising an effective amount of a therapeutic agent and an enteric polymer coating. In some embodiments, the therapeutic agent in the process or dosage form is a polypeptide, a protein, a peptide, a lipopeptide, a glycoprotein, a fusion protein, a protein conjugate, a cytokine, an enzyme, an antibody, an oligonucleotide, a vaccine vector, small molecule, a live virus, an inactivated virus, a virus-like particle, a viral protein subunit, an adjuvant, microbiome, a prebiotic, a probiotic, or an ectobiotic.

Abstract: Disclosed are formulations and tablets made therefrom comprising the compound of Formula IA or Formula IB which have sustained-release properties, and the dispersion containing the compounds of Formula IA or IB which facilitates such sustained release: Formula IA, Formula IB.

Abstract: Cross-machine build scheduling of a codebase is provided. Systems, methods and computer-readable devices provide for breaking a monolithic codebase into a plurality of tenants. A file containing entries associated with one of the tenants is read, and a selected entry in the file is examined to determine if the entry is requesting the execution of parallel loop. If so, each loop of the parallel loops is executed in parallel, and the selected entry in the file is examined to determine if the entry is an independent loop. If so, the independent loop is executed, and the selected entry in the file is examined to determine if the entry is a dependent loop. If so, execution of the dependent loop is held.

Abstract: A composition comprising (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide and hypromellose acetate succinate for pharmaceutical preparations, especially capsule preparations.

Abstract: Facilitating authentication includes providing a first page to a user interface based on an order received from a merchant page. Payment details are received from the first page for a first level of authentication and a second page is provided to the user interface for a second level of authentication. The second page is provided while keeping the first page open in the user interface with the payment details populated therein. A transaction result status is received from a payment-processing infrastructure based on the first and second level of authentication. When the transaction result status indicates failure, a modified first page is created to include the payment details previously populated for an online payment and at least one of a retry button and a field indicating a reason for transaction failure.